Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
Vaccine|September 30, 2023
Evaluation of a stabilized RSV pre-fusion F mRNA vaccine: Preclinical studies and Phase 1 clinical testing in healthy adultsJesse Nussbaum, Xin Cao, Radha A Railkar, et al.
Vaccine|August 21, 2025
Design and preclinical assessment of mRNA-1345 prefusion F glycoprotein-encoding mRNA vaccine for respiratory syncytial virusChristine A Shaw, Guillaume B E Stewart-Jones, Patricia Jorquera, et al.
JAMA|May 7, 2025
Immunogenicity and Safety of Influenza and COVID-19 Multicomponent Vaccine in Adults ≥50 Years: A Randomized Clinical TrialAmanda K Rudman Spergel, Iris Wu, Weiping Deng, et al.
Human Vaccines & Immunotherapeutics|October 30, 2020
A phase 1, randomized, placebo-controlled study to evaluate the safety and immunogenicity of an mRNA-based RSV prefusion F protein vaccine in healthy younger and older adultsAntonios O Aliprantis, Christine A Shaw, Paul Griffin, et al.
The Lancet. Infectious Diseases|November 28, 2024
Safety and immunogenicity of mRNA-1345 RSV vaccine coadministered with an influenza or COVID-19 vaccine in adults aged 50 years or older: an observer-blinded, placebo-controlled, randomised, phase 3 trialJaya Goswami, Jose F Cardona, Denise C Hsu, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 22, 2012
Nonviral delivery of self-amplifying RNA vaccinesAndrew J Geall, Ayush Verma, Gillis R Otten, et al.
Human Vaccines & Immunotherapeutics|February 2, 2026
Phase 1/2 randomized, observer-blind clinical trial of a first-generation, mRNA-based vaccine against seasonal influenza and COVID-19 in healthy adultsAmanda K Rudman Spergel, Carole Henry, Raffael Nachbagauer, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|July 17, 2014
A cationic nanoemulsion for the delivery of next-generation RNA vaccinesLuis A Brito, Michelle Chan, Christine A Shaw, et al.
NPJ Vaccines|March 5, 2020
Modified mRNA/lipid nanoparticle-based vaccines expressing respiratory syncytial virus F protein variants are immunogenic and protective in rodent models of RSV infectionAmy S Espeseth, Pedro J Cejas, Michael P Citron, et al.
The Journal of Infectious Diseases|June 18, 2024
Humoral Immunogenicity of mRNA-1345 RSV Vaccine in Older AdultsJaya Goswami, Abdullah H Baqui, Pablo A Doreski, et al.
Pageof 4